Acute Myeloid Leukemia: Selecting Induction Therapy Based on Biological Disease Factors |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Case Studies in the Management of Leukemia |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Navigating Change: Best Practices for Integrating WHO/ICC Classification Systems in the Management of Hematologic Malignancies |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Management of Newly Diagnosed Multiple Myeloma Based on Risk Stratification |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Incorporating Immunotherapeutic Strategies in the Management of Relapsed/Refractory Multiple Myeloma |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Tackling Inequities in Multiple Myeloma: Practical Steps for Improving Access and Quality of Care |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Advances in the Management of Classical Hodgkin Lymphoma |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Perioperative Management of Anticoagulation and Antithrombotic Therapy |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Updates in the Management of Mantle Cell Lymphoma: Is There Still a Role for Transplant? |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Relapsed/Refractory CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Management of Toxicities of BTK Inhibitors in B-Cell Malignancies |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Bone Disease Management and Infections in Multiple Myeloma |
1.00 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Chronic Myeloid Leukemia/Myelofibrosis: TKI Therapy and Toxicity Management |
0.75 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Management of Graft-Versus-Host Disease in Hematopoietic Cell Transplant Recipients |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |
Management of Lower-Risk Myelodysplastic Syndromes |
0.50 |
12/01/2023 - 12:00am to 12/01/2024 - 12:00am |